Discovery - University of Dundee - Online Publications

Library & Learning Centre

Comparison of Visual and automated assessment of Ki-67 proliferative activity and their impact on outcome in primary operable invasive ductal breast cancer

Comparison of Visual and automated assessment of Ki-67 proliferative activity and their impact on outcome in primary operable invasive ductal breast cancer

Research output: Contribution to journalArticle

View graph of relations

Authors

  • Z. M. A. Mohammed
  • D. C. McMillan
  • B. Elsberger
  • J. J. Going
  • C. Orange
  • E. Mallon
  • J. C. Doughty
  • J. Edwards

Research units

Info

Original languageEnglish
Pages383-388
Number of pages6
JournalBritish Journal of Cancer
Journal publication date17 Jan 2012
Journal number2
Volume106
DOIs
StatePublished

Abstract

BACKGROUND: Immunohistochemistry of Ki-67 protein is widely used to assess tumour proliferation, and is an established prognostic factor in breast cancer. There is interest in automating the assessment of Ki-67 labelling index (LI) with possible benefits in handling increased workload, with improved accuracy and precision.

PATIENTS AND METHODS: Visual and automated assessment of Ki-67 LI and survival were examined in patients with primary operable invasive ductal breast cancer. Tissue microarrays (n=379 patients) immunostained for Ki-67 were scored visually and automatically with the Slidepath Tissue IA system.

RESULTS: Visual and automated Ki-67 LI were in excellent agreement (ICCC=0.96, P<0.001). On univariate analysis, visual (P<0.001) and automated Ki67 LI (P<0.05) were associated with cancer-specific survival in patients with invasive ductal breast cancer overall and in patients who received endocrine therapy (Tamoxifen) (P<0.01 for visual and P<0.05 for automated scoring).

CONCLUSION: Automated assessment of Ki-67 LI would appear to be comparable to visual Ki-67 LI. However, automated Ki-67 LI assessment was inferior in predicting cancer survival in patients with breast cancer, including patients who received Tamoxifen. British Journal of Cancer (2012) 106, 383-388. doi:10.1038/bjc.2011.569 www.bjcancer.com Published online 3 January 2012 (C) 2012 Cancer Research UK

Documents

Library & Learning Centre

Contact | Accessibility | Policy